Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R38 | P59533 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8799476 | 0.87 | KDM4E (0.44) | TAS2R38NOTUMKDM4EMAPTHPGD | |
| SCHEMBL9522651 | 0.81 | CYP2E1 (0.42) | TAS2R38KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL6756097 | 0.79 | TAS2R38 (0.60) | TAS2R38NOTUMKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL8987259 | 0.77 | TAS2R38 (0.44) | TAS2R38NOTUMKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL8222273 | 0.73 | KDM4E (0.50) | KDM4EMAPTSMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL28043530 | 0.73 | KDM4E (0.54) | KDM4EMAPTHPGDALDH1A1CYP3A4 | |
| SCHEMBL28260510 | 0.72 | GCGR (0.49) | KDM4EMAPTHPGDALDH1A1CYP3A4 | |
| SCHEMBL31124 | 0.72 | CYP3A4 (0.58) | KDM4EMAPTHPGDALDH1A1CYP3A4 | |
| SCHEMBL3595434 | 0.72 | TOP1 (0.56) | KDM4EMAPTSMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL8987160 | 0.71 | CYP2E1 (0.53) | TAS2R38NOTUMKDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863793-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-1863793-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20090285774-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
| US-20090285774-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
| US-20090285774-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
| WO-2009140475-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
| US-7323447-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323447-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323447-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1863793-A2 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006086381-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006086381-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060183694-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183694-A1 | Hepatitis C virus inhibitors | HAVCR2, HPN, CTSC | TAS2R38 4313/4885NOTUM 1897/4885KDM4E 2561/4885 |
| US-20090285774-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | TAS2R38 4753/4885NOTUM 1137/4885KDM4E 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.